'Feeling great': Trump's docs say he is no longer Covid transmission risk

Trump returned to action earlier Saturday in a short campaign-style speech to supporters at the White House

Topics
Donald Trump | Joe Biden | Coronavirus

Justin Sink & Niluksi Koswanage | Bloomberg 

It was not clear how the US government would receive part of the purchase price
Trump first unveiled his positive test for the coronavirus early October 2,

U.S. President is no longer considered a transmission risk to others and has met the criteria for safe discontinuation of isolation, according to physician Sean Conley.

Trump has been fever-free for well over 24 hours and all symptoms have improved, Conley said in a memorandum published by the

“The assortment of advanced diagnostic tests obtained reveal there is no longer evidence of actively replicating virus,” Conley wrote. “In addition, sequential testing throughout his illness has demonstrated decreasing viral loads.”

Trump earlier Saturday held his first public event since returning from a three-day hospital stint, thanking hundreds of supporters gathered on the South Lawn for their encouragement during his illness.

The president has announced an aggressive return to the campaign trail following his convalescence, beginning with a rally Monday night in Orlando. He’s expected to visit Pennsylvania on Tuesday and Iowa on Wednesday for additional campaign events.

Conley’s update was the first on the president’s health since Thursday. The has still refused to reveal certain health details about the president and his treatment, including when Trump last tested negative before contracting the

Trump first unveiled his positive test for the early Oct. 2, and has credited his recovery to a Regeneron Pharmaceuticals Inc. antibody cocktail he was administered. The president also received a corticosteroid called dexamethasone as well as Remdesivir, an antiviral manufactured by Gilead Sciences Inc.

“I’m feeling great,” Trump said Saturday, adding that the U.S. was “producing powerful therapies and drugs.”

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Donald Trump
First Published: Sun, October 11 2020. 07:00 IST
RECOMMENDED FOR YOU